Biotest focuses on products in immunology, hematology and intensive care. Founded in 1946 and with > 2000 employees we generated sales of €589.6 million in 2015. Our marketed products use human blood plasma as starting material. They are efficient drugs in life-threatening diseases such as coagulation disorders (hemophilia), severe infections (e.g. Hepatitis B) or disorders of the immune system. Moreover, Biotest is engaged in the development of monoclonal antibodies (including antibody drug conjugates) for treatment of Multiple Myeloma, solid tumor indications, Systemic Lupus Erythematodes (SLE) and further autoimmune diseases.
CEO & Co-Founder, Zapnito
Sales Account Executive, Springer Nature